- For in vitro testing and laboratory use only.
- Not for human or animal consumption.
- Bodily introduction is illegal.
- Handle only by licensed professionals.
- Not a drug, food, or cosmetic.
- Educational use only.
Quick take on IGF-1 LR3
IGF-1 LR3 is a synthetic long-acting analog of insulin-like growth factor-1 — the same hormone your liver produces daily in response to growth hormone, which does most of the actual tissue-building work downstream of the GH signal. Australian researchers at GroPep in Adelaide engineered it in the early 1990s by swapping one amino acid and adding a 13-residue N-terminal extension, and the modification did something dramatic: half-life extended from 10 minutes to 20-30 hours, with roughly three times the biological potency of native IGF-1.
Mechanism in plain English
Native IGF-1 gets captured and neutralized almost immediately by six different binding proteins (IGFBPs) in circulation. LR3's structural changes reduce its affinity for those binding proteins by more than 100-fold, so it stays free and active, hitting IGF-1 receptors directly and persistently across PI3K/Akt (protein synthesis, anti-apoptosis) and MAPK/ERK (cell division) pathways.
What it's used for
People take it for one thing no other peptide delivers: hyperplasia of muscle cells — genuinely adding new muscle cells rather than just enlarging existing ones. Realistic outcomes over a 4-6 week cycle run 1-3 kg of new muscle assuming training and nutrition are dialed in, plus faster recovery and noticeably fuller muscles.
Upsides and downsides
Main upside — LR3 does something mechanistically unique: the MAPK/ERK pathway activation drives actual cell multiplication, which is why experienced users pair it with heavy training to capture growth that persists beyond the cycle.
Main downside — hypoglycemia is the common one (around 40% incidence in clinical data from related mecasermin) and the one that bites users immediately, but the long-term concern is bigger: meta-analyses show high IGF-1 levels correlate with increased risk of prostate, premenopausal breast, and colorectal cancers, and LR3 in anabolic doses pushes IGF receptor activation into territory no epidemiological study has measured. Organomegaly is also real — documented in animal studies as enlarged kidneys, intestines, spleen, and adrenals, which is the mechanism behind the "GH gut" seen in advanced bodybuilders.
Typical protocol
Protocols run 20-50 mcg subcutaneously daily in 4-6 week cycles with equal breaks, always injected with food to blunt hypoglycemia risk. The 20-30 hour half-life means the compound accumulates — steady-state concentrations take 3-5 days to establish, so doubling doses when you "don't feel it" on day two is how people end up hypoglycemic a week later.
Who should skip it
- Anyone with a personal or close family history of cancer.
- Anyone with diabetic retinopathy.
- Anyone with type 1 diabetes.
- Anyone with a cardiac condition.
- Anyone unwilling to run proper bloodwork before, during, and after the cycle.
Regulatory status
Banned by WADA since 2008 under category S2, detectable via LC-MS/MS in both blood and urine. Not approved as a medication; sold as a research chemical.
In your body, insulin-like growth factor 1 (IGF-1) is the actual worker behind growth hormone's reputation. GH itself doesn't do much directly — it travels to the liver, where it triggers IGF-1 production, and IGF-1 does the real anabolic work: building muscle, growing tissue, signaling cells to divide. This is why people pursue GH-raising peptides. They're not really after GH. They're after IGF-1.
But here's a frustration scientists faced in the 1990s: native IGF-1 has a half-life of about 15 minutes in circulation. Almost as soon as you inject it, your body sequesters it inside IGF-binding proteins (IGFBPs), where it sits idle. The active hormone is a tiny fraction of the total. If only there was a way to make IGF-1 that escapes these binding proteins entirely...
In 1992, researchers Francis, Ross, and colleagues at the Cooperative Research Centre for Tissue Growth in Adelaide, Australia, published exactly that molecule. They called it LR3-IGF-1 — Long Arg3 IGF-1 — and it changed research biology. IGFBP binding dropped by roughly 100-fold. Half-life jumped from 15 minutes to 20-30 hours. Potency in living tissue became 2-3 times that of native IGF-1 [1].
And then, inevitably, it leaked out of the research labs and into the bodybuilding world, where it's been used as one of the most potent anabolic peptides available — with risks proportional to that potency.
IGF-1 LR3: what it is and how it works in a nutshell
IGF-1 LR3 is a synthetic 83-amino-acid protein — a modified version of human IGF-1 (70 amino acids) with two key structural changes. It was engineered to do one thing: escape the IGFBP sequestration system and deliver sustained IGF-1 receptor activation.
The two modifications that define it:
- Arg3 substitution — arginine replaces glutamic acid at position 3. This single amino acid change disrupts the critical contact point between IGF-1 and its binding proteins, reducing IGFBP affinity by roughly 100-fold [2].
- N-terminal extension — 13 additional amino acids (Met-Phe-Pro-Ala-Met-Pro-Leu-Ser-Ser-Leu-Phe-Val-Asn) added to the N-terminus further hinder IGFBP binding without affecting receptor recognition.
The result: a molecule that binds the IGF-1 receptor with essentially native potency, but circulates almost entirely in the free, active form.
IGF-1 LR3 is not FDA-approved for human use. Its primary legitimate application is as a growth factor in cell culture media for laboratory research. It has no completed human clinical trials and sits firmly in the "research chemical" category. The bodybuilding use is off-label, unregulated, and carries genuine risks worth understanding.
IGF-1 LR3 mechanism of action: what it actually does in the body
IGF-1 LR3 binds the IGF-1 receptor (IGF-1R) on cell surfaces — the same receptor native IGF-1 uses. Once bound, it triggers two main intracellular pathways:
PI3K / Akt / mTOR pathway. This is the central anabolic signaling cascade in the body. Activation drives protein synthesis, muscle cell proliferation, glucose and amino acid uptake, and suppression of protein breakdown (catabolism). This is how muscle actually grows at the molecular level. mTOR is the same pathway that resistance training activates — IGF-1 LR3 essentially amplifies that signal pharmacologically.
Ras / MAPK / ERK pathway. Drives cell proliferation and differentiation. Activates satellite cells — the muscle stem cells responsible for repairing damaged fibers and creating new ones. This is what distinguishes IGF-1 LR3 from compounds that only enlarge existing muscle fibers: it can actually increase the number of muscle cells (hyperplasia, not just hypertrophy).
Insulin-like metabolic effects. Because IGF-1 is structurally similar to insulin, it also activates the insulin receptor weakly. This creates glucose uptake and hypoglycemia risk that native IGF-1 shares but LR3's extended half-life amplifies significantly.
The practical result of freeing IGF-1 from IGFBP sequestration is sustained, continuous receptor activation over a 20-30 hour window per injection [3]. That's the active mechanism behind the muscle-building and tissue-repair effects. It's also the active mechanism behind the cancer concern — because IGF-1R activation promotes cell proliferation indiscriminately.
Who uses IGF-1 LR3 and what for
- Research labs — the legitimate primary use. IGF-1 LR3 is widely used as a component of cell culture media for growing mammalian cells and tissues in vitro.
- Bodybuilders in advanced cycles — typically stacked with other anabolic agents during mass phases or when trying to break through plateaus. This is the main real-world use, despite being off-label and unapproved.
- Athletes trying to recover from injury — occasionally used for its tissue-repair properties, particularly for tendon and ligament healing.
- Biohackers targeting body recomposition — less common due to the risks involved. Most users in this space choose less potent options.
Realistic expectations over a 4-6 week cycle (the standard use pattern): 2-4 kg of lean mass gain is commonly reported, faster recovery between training sessions, improved nutrient partitioning, subtle changes in skin quality and pump during workouts. Effects are measurable but not transformative — people expecting to look like a different person in 6 weeks will be disappointed.
What WON'T happen: the dramatic results of synthetic anabolic steroids, meaningful fat loss (IGF-1 LR3 is neutral to slightly pro-storage in some contexts), permanent gains that persist without continued use (most gains regress over a few months post-cycle), benefit without training and nutrition alignment.
Here's the honest bottom line: IGF-1 LR3 is one of the most potent single-molecule anabolic peptides available, and also one of the most poorly characterized for long-term human safety.
What IGF-1 LR3 stacks with: popular combinations
- IGF-1 LR3 + GH-raising peptides (CJC-1295 + Ipamorelin) — the logic being that GH peptides stimulate liver IGF-1 production, IGF-1 LR3 adds sustained direct receptor activation. Used by advanced bodybuilders seeking maximum anabolic environment.
- IGF-1 LR3 + BPC-157 or TB-500 — for recovery-focused protocols, especially when injury is being worked around during a training cycle.
- IGF-1 LR3 + MGF (Mechano Growth Factor) — MGF is a local-acting IGF-1 splice variant released during muscle damage. Some users combine them, though the evidence for synergy is thin.
- IGF-1 LR3 + insulin — aggressive bodybuilder stack. Dramatically increases risk of hypoglycemia and should only be considered by people who genuinely understand both compounds. The two together compound each other's metabolic effects significantly.
Generally avoided with: high-dose GLP-1 agonists (unpredictable metabolic interactions), anything else that affects glucose regulation.
IGF-1 LR3 side effects and risks
This section needs to be more detailed than usual because IGF-1 LR3 has a more serious risk profile than most peptides covered on this blog.
- Hypoglycemia — the most immediate practical issue. IGF-1 activates the insulin receptor weakly, and with LR3's extended half-life, glucose can drop noticeably. Post-injection eating is essential. Severe hypoglycemia (shakiness, confusion, sweating, unconsciousness) is a real risk if meals are skipped.
- Localized muscle growth at injection sites — bilateral, symmetric injection rotation matters. Repeatedly injecting the same muscle can produce asymmetric growth.
- Water retention — common in the first 1-2 weeks.
- Joint pain — especially at higher doses, similar to GH-related joint complaints.
- Fatigue and hunger — from glucose fluctuations.
- Organ growth (theoretical concern) — IGF-1 receptors exist on every tissue. Chronic elevation could theoretically affect liver, kidneys, and heart over long periods. Clinical evidence in humans is limited.
The cancer question — this is the serious one. IGF-1R signaling is a well-documented factor in cancer biology. Elevated circulating IGF-1 is associated with increased risk of several cancers (breast, prostate, colorectal) in epidemiological studies [4]. IGF-1 LR3 produces sustained, supraphysiological IGF-1R activation that natural IGF-1 never produces. There is a legitimate biological reason to worry about using this peptide over long periods.
The absence of long-term human safety data isn't a minor caveat — it's a fundamental limitation. Anyone using IGF-1 LR3 is running an uncontrolled experiment on themselves without the protection of clinical trial data.
Who should absolutely avoid:
- Anyone with active cancer or cancer history
- Anyone with strong family history of cancer
- People with diabetic retinopathy or proliferative eye disease (IGF-1 can worsen)
- Pregnant or breastfeeding women
- Anyone under 25 without exceptional medical need
- People with uncontrolled diabetes
- Competitive athletes — IGF-1 and all analogs including LR3 are on the WADA Prohibited List (S2) [5]
How to use and store IGF-1 LR3
Subcutaneous injection is standard. Some users do intramuscular site-targeted injections for localized growth, though the systemic effect is essentially the same with IGF-1 LR3 (unlike native IGF-1, which acts more locally).
Typical protocols:
- Dose: 20-40 mcg per day for men; 10-20 mcg per day for women (women are more sensitive to IGF-1 effects)
- Frequency: once daily — the 20-30 hour half-life means once-daily is sufficient
- Cycle: 4-6 weeks maximum, followed by break of at least equal length
- Timing: post-workout is the most common timing, to leverage the peptide's anabolic effect alongside training-induced anabolic signaling. Always followed by a carbohydrate-containing meal within 30-45 minutes to prevent hypoglycemia.
- Hard limit: continuous use beyond 6 weeks is strongly discouraged. Receptor downregulation and theoretical cancer risk both compound with time.
Storage: lyophilized form at -20°C indefinitely. After reconstitution with bacteriostatic water, refrigerate at 2-8°C and use within 2-3 weeks maximum. Unlike more stable peptides, IGF-1 LR3 in solution degrades faster — don't freeze it once reconstituted.
Labs and monitoring during an IGF-1 LR3 cycle
Monitoring matters more with this peptide than with milder GH-raising stacks.
Before: IGF-1 (baseline), fasting glucose, HbA1c, hematocrit, basic metabolic panel, complete blood count. For anyone over 40 or with risk factors: PSA (men), comprehensive cancer screening appropriate for age.
During (week 2-3): fasting glucose, HbA1c. IGF-1 blood level will be significantly elevated — this is expected.
After: fasting glucose, HbA1c, basic metabolic panel 2-4 weeks post-cycle to confirm normalization.
If any unusual symptoms develop — persistent fatigue, new lumps or swelling, significant vision changes — stop the cycle and see a physician.
IGF-1 LR3 vs alternatives: what's different
- Native IGF-1 — short half-life (15 minutes), mostly IGFBP-bound. Requires frequent dosing, much less practical. Also comparable cancer theoretical risk but at lower sustained levels.
- MGF (Mechano Growth Factor / IGF-1Ec) — local-acting IGF-1 variant. Stimulates satellite cells locally at injection sites. Complementary to IGF-1 LR3 rather than competitive.
- Injected Growth Hormone (somatropin) — stimulates liver IGF-1 production naturally. Broader systemic effects, more regulated feedback, but much more expensive and comes with its own significant side effect profile.
- GH-raising peptides (CJC-1295 + Ipamorelin) — amplify your own natural GH/IGF-1 axis. Much milder effect, much safer profile, still meaningful benefit. For most people pursuing body recomposition, this is the more rational choice.
IGF-1 LR3's distinguishing feature: the most direct, potent, and sustained IGF-1 receptor activation available as a single peptide. That potency is both the attraction and the concern.
Myths about IGF-1 LR3
- "IGF-1 LR3 is safer than anabolic steroids because it's just a natural hormone." This one isn't quite right on multiple levels. First, IGF-1 LR3 is not a natural hormone — it's a modified version engineered specifically to bypass the body's regulatory systems. Second, "safer than steroids" is a low bar that ignores the specific cancer-related concerns IGF-1 LR3 has that steroids don't. Different risk profile, not necessarily a lower one.
- "Site injection causes localized muscle growth." The idea is that injecting into a specific muscle creates larger localized growth. For native IGF-1 with its short half-life, this has some validity. For IGF-1 LR3, the extended half-life means the peptide distributes systemically within hours of injection — localized effects from site injection are minimal. If you want localized effects, MGF is the more logical choice.
Sources
- Francis, G. L., Ross, M., Ballard, F. J., Milner, S. J., Senn, C., McNeil, K. A., Wallace, J. C., King, R., & Wells, J. R. E. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology, 8(3), 213-223. — foundational characterization of IGF-1 LR3.
- Milner, S. J., Francis, G. L., Wallace, J. C., & Ballard, F. J. (1996). Mutations of the pepsin-susceptible bonds in Long-[Arg3]-insulin-like growth factor-I (LR3IGF-I). Growth Factors, 13(3-4), 245-253. — structural basis for reduced IGFBP binding.
- Tomas, F. M., Knowles, S. E., Owens, P. C., Read, L. C., Chandler, C. S., Gargosky, S. E., & Ballard, F. J. (1993). Increased weight gain, nitrogen retention, and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and Long R3-IGF-I. Biochemical Journal, 291(3), 781-786. — foundational in vivo pharmacology study.
- Pollak, M. N., Schernhammer, E. S., & Hankinson, S. E. (2004). Insulin-like growth factors and neoplasia. Nature Reviews Cancer, 4(7), 505-518. — comprehensive review of IGF-1 receptor signaling in cancer biology. Establishes the mechanistic basis for cancer concerns with IGF-1 therapies.
- World Anti-Doping Agency (WADA). Prohibited List — Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. https://www.wada-ama.org — IGF-1 and all analogs including LR3 classification in competitive sport.
- Walton, P. E., Dunshea, F. R., & Ballard, F. J. (1997). Effects of growth hormone and IGF-I peptides on growth performance and IGF, GH, insulin, and IGFBP-3 concentrations in finisher pigs. Journal of Endocrinology, 155(3), 559-567. — one of the few large-animal in vivo studies of LR3-IGF-1 effects.
IGF-1 LR3 Dosage Guide
IGF-1 LR3 (Insulin-like Growth Factor-1 Long Arg3) is an 83-amino-acid synthetic analog of IGF-1 with two modifications — an arginine substitution at position 3 and a 13-amino-acid N-terminal extension — that prevent IGFBP binding and extend the half-life from 12–15 hours to 20–30 hours, making it roughly 3x more potent than native IGF-1. This guide is aimed at experienced users running lean bulking or recomposition cycles, athletes seeking accelerated recovery and muscle hyperplasia, and those combining IGF-1 LR3 with GH secretagogues for compounded anabolic effect. Dosing below combines research protocols (Philippou et al., Tomas et al.), community bodybuilding experience accumulated since the early 2000s, and the receptor downregulation data that has standardized the 4–6 week cycle length.
Real-World Dosage Protocols by Experience Level
| Experience Level | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 20 mcg | Once daily, SC post-workout | First 1–2 weeks; assess hypoglycemia response |
| Standard | 30–40 mcg | Once daily, SC post-workout | Most common protocol; 4-week cycle |
| Intermediate | 50 mcg | Once daily or split AM/PM, SC | Near the anabolic ceiling for most users |
| Aggressive | 60–80 mcg | Split twice daily, SC | Elevated hypoglycemia risk; 4-week max cycle |
| Pulsed / every-other-day | 40–50 mcg | Every 48 hours, SC | Better maintains receptor sensitivity for longer protocols |
| Female | 10–20 mcg | Once daily, SC post-workout | Shorter 4-week cycles recommended |
Doses also shift depending on the specific goal. The same peptide used for lean muscle gain versus local tissue repair can follow quite different protocols.
Dosage by Goal
| Goal | Recommended Dose | Frequency | Cycle Length |
|---|---|---|---|
| Muscle gain / hypertrophy | 30–50 mcg | Once daily, SC post-workout | 4–6 weeks on / 4–6 weeks off |
| Muscle hyperplasia (new muscle cells) | 40–50 mcg | Once daily, SC post-workout, IM for local | 4–6 weeks |
| Recovery / tissue repair | 20–30 mcg | Once daily, SC | 4 weeks |
| Body recomposition / lean bulking | 30–40 mcg | Once daily, SC post-workout | 4–6 weeks |
| Stacked with MK-677 or BPC-157 | 20–30 mcg IGF-1 LR3 + standard stack doses | Once daily, SC | 4–6 weeks |
| Age-related sarcopenia research | 20 mcg | Once daily, SC | 4–6 weeks, cycle twice yearly |
Inject 15–30 minutes post-workout and eat a protein + carbohydrate meal within 30 minutes to prevent hypoglycemia — this is the single most common beginner mistake and causes 20–30% of users to experience shakiness, dizziness, or lightheadedness. Do not chase doses above 50 mcg/day; research shows the anabolic ceiling sits around 40–50 mcg, and higher doses primarily amplify hypoglycemia risk (up to 40% of users) without proportional muscle gain. Absolute contraindications include any cancer history or active diagnosis (IGF-1 is mitogenic), diabetic retinopathy, pregnancy/breastfeeding, uncontrolled diabetes, and users under 21 whose growth plates may not be fully closed — never stack with insulin without medical supervision and separate by at least 6–8 hours if used together.
IGF-1 LR3 Storage Guide: How to Keep Your Research Peptide Stable and Effective
IGF-1 LR3 ships as a white lyophilized powder or cake in a sealed glass vial, freeze-dried to preserve this larger recombinant protein (83 amino acids with disulfide bonds) and extend its shelf life. With a few simple habits — cold, dark, dry — the sealed vial stays in perfect condition for its full shelf life. Here's exactly how to store it.
Lyophilized Powder (Unreconstituted)
| Parameter | Details | Notes |
|---|---|---|
| Storage Temperature | Freezer at −20°C (−4°F) for long-term storage up to 24 months. Refrigeration at 2–8°C (36–46°F) is fine for short-term use up to ~3 months. | Original sealed vial in the freezer is the safest default. |
| Light Sensitivity | Yes — protect from direct light and UV exposure to prevent photodegradation. | Keep in the original box or an opaque, amber container. |
| Freezing | Allowed and recommended. −20°C is standard for long-term storage; −80°C extends stability further if available. | Freeze from the start if you won't use it within 3 months. |
| Structural Integrity | IGF-1 LR3 is a larger recombinant protein with a folded tertiary structure and disulfide bonds, more fragile than small peptides. | Handle the vial gently — avoid dropping, shaking, or jarring, even while frozen. |
| Signs of Degradation | Healthy powder is white to off-white and appears as a uniform cake or loose powder. Watch for yellowing, browning, grey tint, clumping, visible moisture, or a sticky texture. | Any color change, clumping, or moisture = discard the vial. |
| Common Mistakes | Leaving the vial at room temperature after delivery, storing in a frost-free freezer with temperature swings, or opening a cold vial and letting condensation form inside. | Put it in the freezer on arrival, and let sealed vials warm to room temperature before opening. |
Shipping & Product Authenticity
Every order is processed quickly and shipped with full tracking. All products come directly from the official Generic Peptides supply chain — in original manufacturer packaging, carefully handled from warehouse to your door.
Shipping Times
| Destination | Delivery Time | Notes |
|---|---|---|
| USA Domestic | 4–5 business days | Faster when local warehouse stock is selected at checkout |
| International | 13–15 business days | Tracking included; update frequency may vary by destination country |
| Order Processing | 24–48 business hours | Processing begins after payment confirmation |
| Tracking | Provided on all orders | Tracking number sent after dispatch; multiple warehouses may result in separate shipments |
Direct Supply & Secure Delivery
This product is supplied through the official Generic Peptides distribution chain and shipped in original manufacturer packaging. Orders are packed securely to protect the contents during transit and to respect customer privacy as a standard practice.
Outer packaging is neutral and does not display product details on the exterior — a common approach to protect shipments from damage, tampering, and unnecessary exposure during delivery.
What to Expect
- Orders are processed after payment confirmation
- USA domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity & Verified Supply
Every order includes full authenticity assurance: official Generic Peptides presentation, batch-linked lab documentation, and sealed original packaging — giving customers confidence in every purchase.
| Authenticity Feature | Details |
|---|---|
| Packaging | Original manufacturer packaging — sealed and unaltered |
| Lab Documentation | Batch-linked certificate of analysis available on request |
| Supply Chain | Sourced exclusively through official Generic Peptides distribution |
Shipping & Returns
Based on 1 reviews
5.0
Came in with realistic expectations — IGF-1 LR3 isn't magic, it amplifies what you're already doing. Diet and training were dialed in, added this on top and the results accelerated noticeably. Muscle recovery between sessions dropped significantly, fullness stayed even on a slight deficit. Arrived sealed, reconstituted cleanly. Solid product.
IGF-1 LR3 (Long Arginine 3 Insulin-like Growth Factor-1) is a synthetic, modified version of the natural hormone IGF-1. Scientists extended its structure by 13 amino acids and swapped one amino acid at position 3, which makes the molecule about three times more potent and dramatically longer-lasting than natural IGF-1. It is sold strictly as a research chemical — it is not approved by the FDA or other major regulators for performance, bodybuilding, or anti-aging use in humans.
IGF-1 LR3 binds directly to IGF-1 receptors on muscle cells and other tissues, triggering the PI3K/Akt/mTOR pathway — a cascade that boosts protein synthesis, muscle cell proliferation, and glucose uptake. Unlike natural IGF-1, which gets mopped up quickly by IGF binding proteins (IGFBPs), the LR3 version barely interacts with them and stays active in the bloodstream much longer. This means it continues signaling growth and repair for roughly 20–30 hours per injection, compared to minutes for native IGF-1.
In animal and preclinical studies, IGF-1 LR3 has shown strong effects on muscle growth through both hypertrophy (bigger fibers) and hyperplasia (new muscle cells), accelerated tissue repair, improved fat metabolism, and enhanced nutrient partitioning. Users in the bodybuilding community also report faster recovery, better pumps, and some fat loss. That said, human data comes largely from small studies, anecdotal reports, and extrapolations from related molecules like mecasermin — so many of the claimed benefits are not firmly proven in clinical trials.
Commonly cited research protocols use 20 to 50 micrograms per day via subcutaneous injection, with more experienced users going up to 80–100 mcg. Because of its long 20–30 hour half-life, once-daily dosing is standard, and cycles typically run 4 to 6 weeks followed by a break of similar length to avoid receptor downregulation. There is no officially approved human dose — these figures come from user protocols, not regulated clinical guidelines, and unsupervised use carries real risk.
IGF-1 LR3 is supplied as a lyophilized powder that must be reconstituted with bacteriostatic water, then injected subcutaneously using an insulin syringe (usually 29–31 gauge). The abdomen and thigh are common injection sites, and rotating sites helps reduce irritation. Some users inject intramuscularly into a trained muscle believing this creates "site-specific" growth, but research does not clearly support this — the peptide reaches systemic circulation either way.
The most common side effect is hypoglycemia (low blood sugar), because IGF-1 LR3 mimics some insulin-like effects and increases glucose uptake. Users also report headaches, fatigue, injection-site reactions, nausea, and sometimes a pins-and-needles sensation. More serious long-term concerns include potential organ enlargement (heart, kidneys, intestines), acceleration of existing tumors, and insulin resistance. Because it drives cellular growth broadly, anyone with an active cancer or a family history of cancer should not use it.
In most countries, IGF-1 LR3 is not approved for human use and is sold only as a "research chemical" labeled not for human consumption. Buying it for laboratory research is generally legal, but self-injecting it falls into a legal grey area that varies by country. It is explicitly banned by WADA and virtually every major sports governing body, so athletes using it risk failed drug tests and career-ending sanctions — modern tests can detect it in urine and blood.
Natural IGF-1 has a short half-life (roughly 12–20 minutes in free form) because it binds quickly to IGFBPs in the blood, which neutralize most of it. IGF-1 LR3 was specifically engineered to dodge those binding proteins, so far more of the injected dose stays biologically active. The result is roughly three times the potency and a half-life extended to 20–30 hours, meaning one shot of LR3 produces the kind of sustained signaling that would require constant infusion of natural IGF-1.
This is the most serious concern surrounding IGF-1 LR3. IGF-1 is a known growth signal for cells, and elevated IGF-1 levels have been statistically associated in epidemiological studies with higher risk of certain cancers (notably breast, prostate, and colorectal). IGF-1 LR3 does not "cause" cancer in healthy tissue on its own, but by driving cell proliferation broadly, it could theoretically accelerate the growth of pre-existing cancerous or pre-cancerous cells. This is why any history of cancer is considered an absolute contraindication.
The typical users are competitive and recreational bodybuilders looking to push past genetic muscle limits, athletes seeking faster recovery, and a growing group of anti-aging and biohacking enthusiasts chasing improved body composition and skin quality. Some specialty peptide and longevity clinics also offer it off-label under physician supervision. It is not used in mainstream medicine — the closest approved relative is mecasermin (Increlex), prescribed for severe primary IGF-1 deficiency in children with growth failure.
